Recent Posts



  • Layers upon layers. Too many silos. CE, NPS, and now this hybrid of MPA role. All have their own managers, RDs, and EDs. Novartis needs to cutback the leadership levels. Too many chiefs, not enough Indians. With 2025 expected performance being way below expectations, this is where the cuts need to happen.

anonymous
May 17, 2025 at 09:39 AM
  • Thanks for spreading the word about this site and the truth it holds!

anonymous
May 17, 2025 at 09:24 AM
  • HCPs don’t care about indications. Get over it super reps. The Ozempic ship has sailed and it’s not coming back. It’s the natural order of things. What goes up, must come down. Sales, the stock, and soon, the size of the workforce at Novo. All on the decline. Surprised? Then you should be on the LT. I’m sure they’re surprised too. They all have a “best two years ever” hangover.
    Not Ludovic. He has no hangover; RareD struggled immensely over the past two years. He’s just getting ready for the challenge

anonymous
May 17, 2025 at 09:17 AM
  • HCPs don’t care about indications. Get over it super reps. The Ozempic ship has sailed and it’s not coming back. It’s the natural order of things. What goes up, must come down. Sales, the stock, and soon, the size of the workforce at Novo. All on the decline. Surprised? Then you should be on the LT. I’m sure they’re surprised too. They all have a “best two years ever” hangover.
    Not Ludovic. He has no hangover; RareD struggled immensely over the past two years. He’s just getting ready for the challenge.

anonymous
May 17, 2025 at 09:17 AM
  • It was implicitly stated that the board is lacking pharma knowledge. Helge Lund will soon be out, no question.

anonymous
May 17, 2025 at 09:11 AM